Jubilant Pharmova Limited · NSE:JUBLPHARMA
Jubilant Pharmova — Jubilant Life Sciences — Q2 FY2020 Earnings Presentation
27 slides from Jubilant Pharmova's earnings presentation, Oct 25, 2019
Slide 1: Financial Results Quarter Ended Sep 30, 2019
Financial Results Quarter Ended Sep 30, 2019
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Conference Call Details
Conference Call Details Date : October 25, 2019 Time : 05:00 pm IST Replay from : October 25 to November 2, 2019 Dial in No.: +91 22 7194 5757 Playback ID: 27287# 22
Slide 4: Chairmen's Message
Chairmen’s Message JUBILANT Q2’FY20 PERFORMANCE Revenue flat at Rs. 2,266 Crore vs. Q2’FY19; EBITDA at Rs 481 Crore up 6% YoY and 8% QoQ PAT at Rs 249 Crore up 19% YoY and 35% QoQ with EPS of Rs. 15.7 per share vs. Rs 13.5 per share last year Commenting on the Company’s performance, Mr. Shyam S Bhar
Slide 5: Corporate Announcement
Ww Mirescncts Corporate Announcement
Slide 6: Corporate Announcement (1/2)
Corporate Announcement (1/2) Jubilant Life Sciences Limited (JLL), an integrated global Pharmaceuticals and Life Sciences company has announced that the Committee constituted on 26th July, 2019 to consider the option of reorganizing the businesses of the company has recommended the following: i. Dem
Slide 7: Corporate Announcement (2/2)
Corporate Announcement (2/2) Structure post demerger 1. The Pharmaceutical entity will have three businesses viz.- • Pharma business through Jubilant Pharma Limited Singapore (JPL) is engaged in manufacturing and supply of Radiopharmaceuticals with a network of over 50 radio-pharmacies in the US, Al
Slide 8: Rationale of Demerger
Rationale of Demerger Create focused, distinct and separate entities for Pharmaceuticals and LSI business undertakings leading to greater operational efficiencies with dedicated management structure. These distinct business undertakings will enable strategic growth with optimal capital structure
Slide 9: Rationale of Amalgamation
Rationale of Amalgamation Currently, a significant portion of the Promoters’ shareholding in Jubilant Life Sciences is held through a multi-tier structure. The proposed Amalgamations will result in a simplified structure directly identifiable with the Promoters. The current regulatory requiremen
Slide 10: Q2'FY20 Results Analysis
Ww Mirescncts Q2’FY20 Results Analysis
Slide 11: JLL – Q2'FY20 Financial Highlights
JLL – Q2’FY20 Financial Highlights YoY 1 Particulars Q2'FY19 Q2'FY20 Change (%) Revenue flat at Rs 2,266 Crore vs. Q2’FY19 Revenue • Pharmaceuticals revenue at Rs 1,452 Crore, up 9% YoY, contributing 64% to revenue Pharmaceuticals2 1,332 1,452 9% Life Science Ingredients 887 753 (15%) • LSI revenu
Slide 12: Q2'FY20 Adjusted Earnings
Q2’FY20 Adjusted Earnings Consol EBITDA S. No. Particulars Q2'FY19 Q2'FY20 % Change YoY Rs Crore 1 Reported EBITDA 454 481 6% 2 One-off Adjustments 8 23 3 Adjusted EBITDA 462 504 9% 4 Reported EBITDA Margin 20.0% 21.2% 5 Adjusted EBITDA Margin 20.4% 22.2% One-off Expenses S. No. Particulars Q2'FY19
Slide 13: Pharmaceuticals Segment Highlights – Q2'FY20 (1/2)
Pharmaceuticals Segment Highlights – Q2’FY20 (1/2) Particulars1 Q2'FY19 Q2'FY20 % Change Pharmaceuticals revenue at Rs 1,452 Crore, up 9% both YoY and QoQ Revenue 1,332 1,452 9% Specialty Pharma 712 743 4% • Healthy growth in all key revenue segments led by 20% YoY CDMO 372 411 10% growth in Gener
Slide 14: Pharmaceuticals Segment Highlights – Q2'FY20 (2/2)
Pharmaceuticals Segment Highlights – Q2’FY20 (2/2) USFDA Inspection Details CDMO1 Revenue up by 10% YoY and 19% QoQ to Rs 411 Crore Facility Last Inspection CMO Montreal, CMO May, 2018 Growth in CMO business led by higher volumes from existing customers Montreal, Radiopharma Sep, 2017 Initiati
Slide 15: LSI Segment Highlights – Q2'FY20
LSI Segment Highlights – Q2’FY20 Particulars1 Q2'FY19 Q2'FY20 % Change LSI revenue at Rs 753 Crore, down 15% YoY and 7% QoQ mainly due to Revenue 887 753 (15%) • Strong growth in Specialty Intermediates and Nutritional Specialty Intermediates 196 259 32% Products Nutritional Products 107 113 6% •
Slide 16: Drug Discovery & Development Solutions – Q2'FY20
Drug Discovery & Development Solutions – Q2’FY20 Particulars1 Q2'FY19 Q2'FY20 % Change Drug Discovery & Development Solutions (DDDS) comprises Revenue 50 61 20% • Drug Discovery Services business through Jubilant Biosys Limited Drug Discovery Services 50 61 20% & Jubilant Chemsys Limited which pro
Slide 17: Proprietary Drug Discovery (Jubilant Therapeutics)
Proprietary Drug Discovery (Jubilant Therapeutics) Jubilant Therapeutics, a subsidiary of Jubilant Life Sciences for proprietary innovation, is a capital efficient, semi-virtual biopharma with agile business model and asset specific subsidiaries for creative partnerships. The company’s core stra
Slide 18: H1'FY20 Results Analysis
H1’FY20 Results Analysis 17 17
Slide 19: JLL – H1'FY20 Financial Highlights
JLL – H1’FY20 Financial Highlights 1 YoY H1'FY19 H1'FY20 Particulars Change (%) Revenue at Rs 4,448 Crore up 2% from Rs 4,348 Crore in H1’FY19 Revenue • Pharmaceuticals revenue at Rs 2,781 Crore, up 10% YoY, contributing Pharmaceuticals2 2,519 2,781 10% Life Science Ingredients 1,734 1,559 (10%) 6
Slide 20: H1'FY20 Adjusted Earnings
H1’FY20 Adjusted Earnings Consol EBITDA S. No. Particulars H1'FY19 H1'FY20 % Change YoY Rs Crore 1 Reported EBITDA 901 925 3% 2 One-off Adjustments 13 71 3 Adjusted EBITDA 914 996 9% 4 Reported EBITDA Margin 20.7% 20.8% 5 Adjusted EBITDA Margin 21.0% 22.4% One-off Expenses S. No. Particulars H1'FY19
Slide 21: Pharmaceuticals Segment Highlights – H1'FY20
Pharmaceuticals Segment Highlights – H1’FY20 Particulars1 H1'FY19 H1'FY20 % Change Geography Wise Revenue1 Revenue 2,519 2,781 10% 2,061 2,299 Specialty Pharma 1,377 1,468 7% CDMO 649 756 16% Generics 493 557 13% 55 66 241 221 162 195 Reported EBITDA 699 716 2% Adjusted EBITDA 712 778 9% India North
Slide 22: LSI Segment Highlights – H1'FY20
LSI Segment Highlights – H1’FY20 Life Science Chemicals Segment LSI revenue at Rs 1,559 Crore, down 10% YoY Particulars1 H1'FY19 H1'FY20 % Change EBITDA at Rs 213 Crore down 3% YoY with margin of 13.7% as Revenue 1,734 1,559 (10%) compared to 12.6% in H1’FY19. Adjusted EBITDA up 1% YoY to Rs Spe
Slide 23: Drug Discovery & Development Solutions – H1'FY20
Drug Discovery & Development Solutions – H1’FY20 Particulars1 H1'FY19 H1'FY20 % Change DDDS segment revenue up 14% YoY to Rs 109 Crore led by Revenue 95 109 14% growth in Drug Discovery Services business which was driven Drug Discovery Services 95 109 14% by higher demand from Biotech companies fo
Slide 24: Debt Profile
Debt Profile Particulars 31/03/19 30/06/19 30/09/19 Foreign Currency Loans ($ Mn) ($ Mn) ($ Mn) Subsidiaries 500 500 500 Total 500 500 500 Rupee Loans (Rs. Crs) (Rs. Crs) (Rs. Crs) Standalone 1,341 1,056 1,029 Subsidiaries 61 95 21 Total 1,402 1,151 1,050 Gross Debt (Rs. Crs) (Rs. Crs) (Rs. Crs) Sta
Slide 25: Appendix
Ww Mirescncts Appendix 24
Slide 26: Income Statement – Q2 & H1'FY20
Income Statement – Q2 & H1’FY20 Particulars1 Q2'FY19 Q2'FY20 YoY Growth H1'FY19 H1'FY20 YoY Growth Total Revenue from Operations 2,269 2,266 (0%) 4,348 4,448 2% Pharmaceuticals 1,332 1,452 9% 2,519 2,781 10% Life Science Ingredients 887 753 (15%) 1,734 1,559 (10%) Drug Discovery & Development Soluti
Slide 27: For more information
For more information For Investors: Ravi Agrawal/Vineet V Mayer Siddharth Rangnekar Jubilant Life Sciences Limited CDR India Ph: +91 120 436 1002 / 1021 Ph: +91 22 6645 1209 E-mail: ravi.Agrawal@jubl.com E-mail: siddharth@cdr-india.com Vineet.mayer@jubl.com For Media: Gaurav Kashyap Sudhakar Safaya
Jubilant Life Sciences — Q2 FY2020 Earnings Presentation on 6ix